← Eichor
Study identifier: NCT05057052 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis

Condition: Liver Metastases · Colorectal Cancer Metastatic  ·  Sponsor: Fudan University

PhasePhase 2
Planned participants25
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The objective of this study is to evaluate the efficacy and safety of cryoablation combined with Sintilimab plus regorafenib for patients with colorectal cancer liver metastasis in the third-line setting.

This description comes directly from the study's public registry record.

Talk to the study team

Peng Wang, MD  ·  86-21-64175590  ·  peng_wang@fudan.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05057052